Natalie C Ward1, Janis M Nolde1, Justine Chan1, Revathy Carnagarin1, Gerald F Watts2,3, Markus P Schlaich4,5,6. 1. Dobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia. 2. Medical School, University of Western Australia, Perth, Australia. 3. Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth, Australia. 4. Dobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia. markus.schlaich@uwa.edu.au. 5. Departments of Cardiology & Nephrology, Royal Perth Hospital, Perth, Australia. markus.schlaich@uwa.edu.au. 6. Neurovascular Hypertension & Kidney Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia. markus.schlaich@uwa.edu.au.
Abstract
PURPOSE OF REVIEW: To provide an overview of the associations between elevated blood pressure and lipoprotein (a) and possible causal links, as well as data on the prevalence of elevated lipoprotein (a) in a cohort of hypertensive patients. RECENT FINDINGS: Elevated lipoprotein (a) is now considered to be an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Despite this, there are limited data demonstrating an association between elevated lipoprotein (a) and hypertension. Further, there is limited mechanistic data linking lipoprotein (a) and hypertension through either renal impairment or direct effects on the vasculature. Despite the links between lipoprotein (a) and atherosclerosis, there are limited data demonstrating an association with hypertension. Evidence from our clinic suggests that ~ 30% of the patients in this at-risk, hypertensive cohort had elevated lipoprotein (a) levels and that measurement of lipoprotein (a) maybe useful in risk stratification.
PURPOSE OF REVIEW: To provide an overview of the associations between elevated blood pressure and lipoprotein (a) and possible causal links, as well as data on the prevalence of elevated lipoprotein (a) in a cohort of hypertensive patients. RECENT FINDINGS: Elevated lipoprotein (a) is now considered to be an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Despite this, there are limited data demonstrating an association between elevated lipoprotein (a) and hypertension. Further, there is limited mechanistic data linking lipoprotein (a) and hypertension through either renal impairment or direct effects on the vasculature. Despite the links between lipoprotein (a) and atherosclerosis, there are limited data demonstrating an association with hypertension. Evidence from our clinic suggests that ~ 30% of the patients in this at-risk, hypertensive cohort had elevated lipoprotein (a) levels and that measurement of lipoprotein (a) maybe useful in risk stratification.
Authors: J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn Journal: Nature Date: 1987 Nov 12-18 Impact factor: 49.962
Authors: Katrina L Ellis; Michael B Boffa; Amirhossein Sahebkar; Marlys L Koschinsky; Gerald F Watts Journal: Prog Lipid Res Date: 2017-09-06 Impact factor: 16.195
Authors: Robert Clarke; John F Peden; Jemma C Hopewell; Theodosios Kyriakou; Anuj Goel; Simon C Heath; Sarah Parish; Simona Barlera; Maria Grazia Franzosi; Stephan Rust; Derrick Bennett; Angela Silveira; Anders Malarstig; Fiona R Green; Mark Lathrop; Bruna Gigante; Karin Leander; Ulf de Faire; Udo Seedorf; Anders Hamsten; Rory Collins; Hugh Watkins; Martin Farrall Journal: N Engl J Med Date: 2009-12-24 Impact factor: 91.245
Authors: George Thanassoulis; Catherine Y Campbell; David S Owens; J Gustav Smith; Albert V Smith; Gina M Peloso; Kathleen F Kerr; Sonali Pechlivanis; Matthew J Budoff; Tamara B Harris; Rajeev Malhotra; Kevin D O'Brien; Pia R Kamstrup; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Matthew A Allison; Thor Aspelund; Michael H Criqui; Susan R Heckbert; Shih-Jen Hwang; Yongmei Liu; Marketa Sjogren; Jesper van der Pals; Hagen Kälsch; Thomas W Mühleisen; Markus M Nöthen; L Adrienne Cupples; Muriel Caslake; Emanuele Di Angelantonio; John Danesh; Jerome I Rotter; Sigurdur Sigurdsson; Quenna Wong; Raimund Erbel; Sekar Kathiresan; Olle Melander; Vilmundur Gudnason; Christopher J O'Donnell; Wendy S Post Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245